MoonLake Immunotherapeutics Newsroom

Stifel Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $77

Moomoo NewsApr 10 15:31 ET

Cantor Fitzgerald Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating

Moomoo NewsApr 4 13:31 ET

BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $81

Moomoo NewsMar 19 13:31 ET

Guggenheim Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $80

Moomoo NewsMar 18 13:32 ET

RBC Capital Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $67

Moomoo NewsMar 18 13:32 ET

MoonLake Immunotherap Price Target Announced at $67.00/Share by RBC Capital

Dow JonesMar 18 11:40 ET

MoonLake Analyst Ratings

BenzingaMar 18 11:30 ET

Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target

MT NewswiresMar 18 06:35 ET

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target

MT NewswiresMar 18 06:28 ET

LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75

Moomoo NewsMar 17 13:32 ET

TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating

Moomoo NewsMar 12 18:31 ET

H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100

Moomoo NewsFeb 28 06:34 ET

Goldman Sachs Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $73

Moomoo NewsFeb 27 10:32 ET

A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $66 to $100

Moomoo NewsFeb 27 08:01 ET

MoonLake Immunotherap Is Maintained at Buy by Needham

Dow JonesFeb 27 04:58 ET

MoonLake Analyst Ratings

BenzingaFeb 27 04:48 ET

Needham Maintains Buy on MoonLake, Raises Price Target to $66

BenzingaFeb 27 04:48 ET

Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments

TipRanksFeb 26 12:32 ET

Goldman Sachs Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $82

Moomoo NewsJan 17 06:33 ET

Goldman Sachs Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Raises Target Price to $82

Moomoo NewsJan 16 16:32 ET